Related Experiment Video
Updated: Jul 7, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Emerging therapies for refractory angina
Daniel Satran1, Jay H Traverse, Gregory W Barsness
1Division of Cardiovascular Disease, Minneapolis Heart Institute Foundation/Abbott Northwestern Hospital, University of Minnesota, USA.
Insights
Patients with refractory angina, often termed "no-option" patients, face challenges with traditional treatments. Emerging therapies offer new hope for managing severe coronary artery disease symptoms.
Area of Science:
- Cardiology
- Vascular Medicine
- Regenerative Medicine
Background:
- Advances in pharmacologic and revascularization therapies have improved survival for coronary artery disease (CAD) patients.
- Increased longevity leads to a growing population of CAD patients with extensive disease.
Observation:
- Many long-living CAD patients develop myocardial ischemia and angina unresponsive to standard revascularization.
- These patients are classified as having refractory angina or are considered "no-option" cases.
Findings:
- The article reviews current clinical management strategies for refractory angina.
- Emerging therapeutic options are discussed, including enhanced external counterpulsation, therapeutic angiogenesis, neurostimulation, and transmyocardial revascularization.
Implications:
- Provides a comprehensive overview of management for a challenging patient group.
- Highlights novel treatment avenues for severe, symptomatic chronic coronary artery disease.
- Offers insights into improving quality of life for "no-option" angina patients.
Abstract:
In recent years, improvements in both pharmacologic and revascularization therapies have greatly increased life expectancy for patients with coronary artery disease (CAD). As patients with more extensive CAD live longer, many develop myocardial ischemia and clinical angina that is not amenable to traditional revascularization therapy. Patients with severe, symptomatic, chronic CAD have been described as having refractory angina; they have also been termed "no-option" patients. This article discusses clinical management of this unique and growing group of patients and emerging therapeutic options including pharmacologic agents, enhanced external counterpulsation therapy, therapeutic angiogenesis, neurostimulation, and transmyocardial revascularization.
Related Concept Videos
Angina IV: Management
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care
Angina V: Nursing Management
Angina II: Classification
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
